Anti-Müllerian Hormone: What This Fertility Blood Test Can and Cannot Tell You
AMH is the best available blood test for ovarian reserve but can't reliably predict pregnancy, and the lack of standardized testing means lab results aren't always comparable.
Quick Facts
What This Study Found
Anti-Müllerian hormone (AMH) remains the preferred blood marker for assessing functional ovarian reserve — the pool of growing follicles that could potentially lead to ovulation. Serum AMH is used to personalize fertility drug dosing and can predict the risk of poor response or ovarian hyperstimulation during IVF, though it has limited ability to predict actual pregnancy success.
AMH may also help predict when a woman will reach menopause, though the rate of age-related AMH decline varies significantly between individuals. A major ongoing limitation is the lack of an international standard for AMH measurement, making it difficult to compare results across different lab tests.
Key Numbers
AMH reflects functional ovarian reserve · Used in individualized FSH dosing · Predicts poor response and hyperstimulation risk · Limited value for predicting ongoing pregnancy · No international measurement standard
How They Did This
Systematic literature review using PubMed to identify recent publications on serum AMH measurement and its clinical applications in ovarian reserve assessment.
Why This Research Matters
AMH testing has become a cornerstone of fertility medicine, influencing treatment decisions for millions of women undergoing IVF and fertility assessments. Understanding what AMH can and cannot tell clinicians is critical — it's excellent for gauging ovarian reserve and drug dosing but shouldn't be over-interpreted as a pregnancy predictor. The lack of standardized assays means results from different labs may not be directly comparable, which affects clinical decision-making.
The Bigger Picture
AMH testing has exploded in popularity, with direct-to-consumer fertility testing companies now marketing it broadly. This review provides important context: while AMH is the best tool available for ovarian reserve assessment, it's being used — and sometimes over-marketed — beyond what the science supports. The push for assay standardization is critical as AMH testing becomes more widespread in routine clinical care and consumer health.
What This Study Doesn't Tell Us
The review highlights that AMH assay standardization remains unresolved — different tests can give different values for the same sample. Little is known about endogenous and exogenous factors (like medications, BMI, or ethnicity) that influence AMH levels. The review itself is limited to published literature and may not capture all emerging assay technologies.
Questions This Raises
- ?When will an international AMH measurement standard be established so results are comparable across labs?
- ?What endogenous and exogenous factors (medications, BMI, ethnicity) meaningfully affect AMH levels?
- ?Should direct-to-consumer AMH tests include stronger disclaimers about the test's limitations in predicting pregnancy?
Trust & Context
- Key Stat:
- Preferred marker AMH remains the best blood test for ovarian reserve, but no international measurement standard exists, making cross-lab comparisons unreliable
- Evidence Grade:
- This is a narrative review published in a top endocrinology journal. It synthesizes existing clinical evidence on AMH utility and limitations but does not generate new data.
- Study Age:
- Published in 2020 in the Journal of Clinical Endocrinology & Metabolism. The core findings about AMH's clinical utility and standardization challenges remain highly relevant today.
- Original Title:
- Anti-Müllerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function.
- Published In:
- The Journal of clinical endocrinology and metabolism, 105(11), 3361-73 (2020)
- Authors:
- Moolhuijsen, Loes M E, Visser, Jenny A(2)
- Database ID:
- RPEP-05007
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can an AMH test tell me if I can get pregnant?
Not directly. AMH measures your pool of growing ovarian follicles — essentially your egg supply — but it has limited ability to predict whether you'll actually become pregnant. Women with low AMH can still conceive naturally, and women with high AMH don't always. It's most useful for guiding fertility treatment decisions, not for predicting pregnancy on its own.
Why might AMH results differ between labs?
There is no international standard for how AMH is measured. Different labs use different assay technologies (including newer automated ones), and results from one test may not be directly comparable to another. This is a recognized problem in the field, and efforts to create a universal standard are ongoing.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05007APA
Moolhuijsen, Loes M E; Visser, Jenny A. (2020). Anti-Müllerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function.. The Journal of clinical endocrinology and metabolism, 105(11), 3361-73. https://doi.org/10.1210/clinem/dgaa513
MLA
Moolhuijsen, Loes M E, et al. "Anti-Müllerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function.." The Journal of clinical endocrinology and metabolism, 2020. https://doi.org/10.1210/clinem/dgaa513
RethinkPeptides
RethinkPeptides Research Database. "Anti-Müllerian Hormone and Ovarian Reserve: Update on Assess..." RPEP-05007. Retrieved from https://rethinkpeptides.com/research/moolhuijsen-2020-antimllerian-hormone-and-ovarian
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.